ReviewCNS neuroscience & therapeutics2013
Quetiapine fumarate for the treatment of multiple sclerosis: focus on myelin repair.
Review in CNS neuroscience & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02087631 (A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Recent Advances in Interventions Targeting Remyelination and a Systematic Review of Remyelinating Effects of Approved Disease-Modifying Treatments for Multiple Sclerosis.European journal of neurology · 2025Pooled it
- The deficit of oligodendrocyte family cells in layer 3 of the dorsal anterior cingulate cortex in schizophrenia: possible interactions with dysfunction and altered microanatomy.European archives of psychiatry and clinical neuroscience · 2026Article
- Effects of quetiapine on cognitive functioning in schizophrenia: evidence for the remyelination hypothesis?European archives of psychiatry and clinical neuroscience · 2026Article
- Deficit of oligodendrocyte family cells in layer 5 of the dorsal anterior cingulate cortex in schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Altered Lipid Metabolism in CNS Demyelination and Remyelination Are Key Elements Driving Progressive MS.International journal of molecular sciences · 2025Review
- Deficit of satellite oligodendrocytes of neurons in the rostral part of the head of the caudate nucleus in schizophrenia.European archives of psychiatry and clinical neuroscience · 2025Article
- Enhancing remyelination in multiple sclerosis via M1 muscarinic acetylcholine receptor.Molecular pharmacology · 2025Review
- Overview of emerging therapies for demyelinating diseases.World journal of clinical cases · 2024Review
- Axo-glial interactions between midbrain dopamine neurons and oligodendrocyte lineage cells in the anterior corpus callosum.Brain structure & function · 2023Article
- Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis.International journal of molecular sciences · 2023Review
- Enhancers of Human and Rodent Oligodendrocyte Formation Predominantly Induce Cholesterol Precursor Accumulation.ACS chemical biology · 2022Article
- Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis.Clinical and translational science · 2022Article
- [Acute psychotic episode as a primary clinical manifestation of multiple sclerosis-a case report].Der Nervenarzt · 2022Article
- Central nervous system diseases related to pathological microglial phagocytosis.CNS neuroscience & therapeutics · 2021Review
- The Current Challenges for Drug Discovery in CNS Remyelination.International journal of molecular sciences · 2021Review
- The Synergistic Anti-Apoptosis Effects of Amniotic Epithelial Stem Cell Conditioned Medium and Ponesimod on the Oligodendrocyte Cells.Frontiers in pharmacology · 2021Article
- Article
- The evolving role of neuro-immune interaction in brain repair after cerebral ischemic stroke.CNS neuroscience & therapeutics · 2018Review
- Review
- Disease-Modifying Treatment in Progressive Multiple Sclerosis.Current treatment options in neurology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a central nervous system disorder that is associated with progressive oligodendrocyte and neuronal loss, axonal degeneration, and demyelination. Several medications that mitigate immune abnormalities reduce both the frequency of relapses and inflammation on magnetic resonance imaging, leading to improved outcomes for people with the relapsing-remitting form of MS. However, there are no treatments for the progressive forms of MS where neurons and axons continue to degenerate; here, neuroprotective therapies, or medications that rebuild myelin to confer axonal well-being, may be useful. Quetiapine fumarate is an atypical antipsychotic with reported remyelinating and neuroprotective properties in inflammatory and noninflammatory models of demyelination, including experimental autoimmune encephalomyelitis, and both cuprizone- and global cerebral ischemia-induced demyelination. Preclinical studies suggest that quetiapine may exert these effects by stimulating proliferation and maturation of oligodendrocytes, releasing neurotrophic factors, increasing antioxidant defences, scavenging for free radicals, and inhibiting activated microglia, astrocytes, and T lymphocytes. Additionally, quetiapine may be beneficial for psychiatric and nonpsychiatric symptoms of MS including depression, anxiety, insomnia, and possibly even pain. These data indicate that clinical trials are justified to determine the safety, tolerability, and efficacy of quetiapine fumarate in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.